Beacon Therapeutics reports promising 6-month data on laru-zova, showing visual function improvements in XLRP patients from the DAWN trial.
Quiver AI Summary
Beacon Therapeutics announced promising interim results from its Phase 2 DAWN trial of laru-zova, a gene therapy for X-linked retinitis pigmentosa (XLRP), presented at the ARVO 2025 Annual Meeting. Six-month data indicated that laru-zova was well-tolerated and showed improvements in visual function, particularly in low luminance visual acuity and microperimetry measures. The therapy aims to restore normal function in retinal cells by delivering a functional copy of the RPGRORF15 gene. No serious adverse reactions were reported, and the study is currently enrolling participants for the pivotal Phase 2/3 VISTA trial to further assess laru-zova's efficacy and safety. XLRP is a genetic retinal disease affecting approximately 1 in 25,000 males, leading to severe vision loss without existing treatments.
Potential Positives
- 6-month interim safety and efficacy results from the Phase 2 DAWN trial show promising improvements in visual function for laru-zova, suggesting its potential as an effective treatment for X-linked retinitis pigmentosa (XLRP).
- Laru-zova was well-tolerated by participants, with no serious adverse reactions reported, indicating a favorable safety profile for this investigational therapy.
- The therapy has received several designations, including Regenerative Medicine Advanced Therapy and Fast Track from the FDA, enhancing its development prospects and signaling its potential significance in treating XLRP.
Potential Negatives
- The press release does not provide detailed information on long-term safety and efficacy, which is crucial for assessing the overall impact of laru-zova, leaving uncertainty about its sustained performance beyond the 6-month interim results.
- While the reported ocular treatment-emergent adverse events (TEAEs) were generally mild or moderate, the mention of related surgical procedures raises concerns about the overall safety profile and could deter potential trial participants or investors.
- The company is still in the Phase 2 of the clinical trial process with no FDA approval yet, indicating that laru-zova is still uncertain in its journey to commercialization, which may affect investor confidence.
FAQ
What are the results of the DAWN trial for laru-zova?
The DAWN trial showed significant improvements in visual function and was generally well-tolerated by participants at 6 months.
What is laru-zova used for?
Laru-zova is a gene therapy being investigated for treating X-linked retinitis pigmentosa (XLRP), aiming to restore retinal function.
Who is affected by XLRP?
XLRP primarily affects males, with approximately 1 in 25,000 males being impacted due to mutations in the RPGR gene.
What distinguishes laru-zova's treatment approach?
Laru-zova aims to restore vision by delivering a functional copy of the RPGR gene, targeting both rods and cones in the retina.
How can I learn more about Beacon Therapeutics?
Visit their website at beacontx.com for more information on their research and development initiatives.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry
Laru-zova was generally well-tolerated by DAWN participants at 6 months
LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis pigmentosa (XLRP) at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting being held May 4-8, 2025 in Salt Lake City. Laru-zova was generally well-tolerated by all DAWN participants evaluated at 6 months or beyond and initial data showed promising improvements in visual function across several key measures.
“Over the past five years we have built a compelling body of safety and efficacy data on laru-zova across three different clinical studies,” said Lance Baldo, M.D., Chief Executive Officer of Beacon Therapeutics. “We are pleased to be sharing the 6-month data update from the DAWN Phase 2 study that continues to demonstrate laru-zova's potential to enhance vision in patients with XLRP, including improvements in multiple measures of visual function. We look forward to continuing the advancement of this exciting novel treatment option for patients suffering from XLRP.”
XLRP is an inherited retinal disease often caused by mutations to the RPGR gene, affecting 1 in 25,000 males in the U.S., Europe and Australia. The disease often leads to blindness by middle age, with no available treatment options. Laru-zova is a potential best-in-class gene therapy designed to restore the natural function of both rods and cones in XLRP by delivering a functional copy of the RPGR ORF15 gene using a well-established vector with a proprietary capsid designed for high transduction of photoreceptors, and a codon-optimized gene to produce the full-length protein.
Key data highlights include:
- Ocular treatment-emergent adverse events (TEAEs) were generally non-serious and mild or moderate in severity, with a majority related to surgical procedures and steroids required by the protocol that have since resolved. There were no suspected unexpected serious adverse reactions, retinal detachments or endophthalmitis reported.
- Data demonstrated early improvements in low luminance visual acuity (LLVA), an important measure of visual function, with a greater number of two and three line improvements in the study eyes compared to previously treated fellow eyes in participants evaluated at month 6 or beyond.
-
Data also showed early and sustained improvements in mean sensitivity in study eyes, as observed by microperimetry, indicating enhanced visual function in participants evaluated at month 6 or beyond.
DAWN is an open-label study of laru-zova in participants with XLRP who have previously been treated with a full-length AAV vector-based gene therapy targeting the RPGR protein. The study aims to assess two dose levels of laru-zova for efficacy, safety and tolerability in the untreated eye of participants who previously received gene therapy for XLRP.
The Company continues to enroll patients for its pivotal Phase 2/3 VISTA trial of laru-zova for patients with XLRP.
Presentation Title: Subretinal gene therapy laru-zova (AGTC-501) for X-linked retinitis pigmentosa (XLRP): Phase 2 DAWN preliminary month 6+ results
Presenting Author: Mark Pennesi, M.D., Ph.D., FARVO, Director, Ophthalmic Genetics at the Retina Foundation in Dallas, Texas; Professor of Ophthalmology and Professor of Molecular and Medical Genetics, and Chief of the Paul H. Casey Ophthalmic Genetics Division at the Casey Eye Institute, Oregon Health and Science University in Portland, Oregon
Contact:
[email protected]
Media & Investors:
[email protected]
About laru-zova
Laru-zova (laruparetigene zovaparvovec) is a potential best-in-class gene therapy currently being investigated for the treatment of patients with X-linked retinitis pigmentosa (XLRP). Laru-zova has the potential to restore the natural function of both rods and cones in XLRP by delivering a functional copy of the RPGR ORF15 gene designed to produce the full-length protein. Laru-zova has Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration (FDA), Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), Innovative Licensing and Access Pathway (ILAP) from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), as well as Orphan Drug Designation (ODD) from the FDA and EMA.
Laru-zova is investigational and has not been approved by FDA for use.
About the DAWN and VISTA Studies
DAWN ( NCT06275620 ) is a Phase 2, open-label study of laru-zova in the fellow eye of male participants with XLRP who have previously been treated with an AAV vector-based gene therapy delivering the full-length RPGR protein. The objective of DAWN is to assess two different dose levels of laru-zova for efficacy, safety and tolerability in the target population. DAWN is also evaluating the changes in visual function and functional vision, and is the first trial in the laru-zova clinical development program that is collecting and evaluating low luminance visual acuity (LLVA) data.
VISTA ( NCT04850118 ) is a Phase 2/3, randomized, controlled, masked, multi-center pivotal study evaluating the efficacy, safety and tolerability of laru-zova in two study groups compared to an untreated control group. The study will evaluate the proportion of participants with a 15 or more letter increase from baseline in LLVA and additional measures of functional vision. The VISTA study is currently enrolling.
About XLRP
X-linked retinitis pigmentosa (XLRP) is an inherited retinal disease that predominantly affects males, typically caused by mutations in the retinitis pigmentosa GTPase regulator ( RPGR ) gene. The mutations, which affect approximately 1 in 25,000 males in the U.S., Europe and Australia, result in progressive photoreceptor loss over time and visual dysfunction beginning in childhood, eventually leading to blindness and impacting quality of life with no approved treatments.
About Beacon Therapeutics
Beacon Therapeutics is a clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases. The Company has an established scientific foundation that includes a late-stage clinical development candidate to treat XLRP and two preclinical programs targeting dry age-related macular degeneration (AMD) and an inherited cone-rod dystrophy (CRD).
Beacon Therapeutics’ investors include Syncona Limited, Forbion, Oxford Science Enterprises, TCGX and Advent Life Sciences, among others. Learn more about Beacon Therapeutics at beacontx.com .
